GC Aesthetics® (GCA), a privately-owned company providing aesthetic and plastic surgery solutions, has launched a major multi-centre clinical study in Europe to assess the safety, effectiveness, and patient satisfaction of the innovative PERLE™ smooth opaque round breast implant.

This extensive study includes leading surgeons from both the National Health Service (NHS) and private practices across the UK and Europe, ensuring a wide range of data covering aesthetic and plastic surgery applications.

The study aims to generate high-quality clinical evidence to demonstrate the benefits of the PERLE™ Implant, setting a new standard in breast implant technology and patient care.

PERLE™ is a cutting-edge breast implant that features a patented surface technology (BioQ™), GCA’s advanced Emunomic™ Breast Tissue Dynamic Gel, and enhanced safety features, all of which contribute to the company’s longstanding focus on safety.

The clinical research will collect extensive data from a large sample size to confirm the implant’s safety and effectiveness over the long term, helping both patients and clinicians make informed decisions about breast implants.

GC Aesthetics remains committed to innovation and evidence-based solutions, focusing on meeting the needs of patients and surgeons worldwide. This study underscores the company’s dedication to advancing clinical practice while maintaining a strong reputation for high-quality, safe, and patient-centred care.

The results of this study will further strengthen the company’s product portfolio and enhance its position as a trusted provider of breast implant solutions globally.



Source: businesswire.com

Report Abuse